DNA methylation in prostate cancer

ACS, 2004, 1 Rodriguez, 1997, Family history and risk of fatal prostate cancer, Epidemiology, 8, 653, 10.1097/00001648-199710000-00007 Neugut, 2004, The skinny on obesity and prostate cancer prognosis, J. Clin. Oncol., 22, 395, 10.1200/JCO.2004.11.973 Yoder, 1997, Cytosine methylation and the ecology of intragenomic parasites, Trends Genet., 13, 335, 10.1016/S0168-9525(97)01181-5 Bird, 1986, CpG-rich islands and the function of DNA methylation, Nature, 321, 209, 10.1038/321209a0 Gardiner-Garden, 1987, CpG islands in vertebrate genomes, J. Mol. Biol., 196, 261, 10.1016/0022-2836(87)90689-9 Esteller, 2001, A gene hypermethylation profile of human cancer, Cancer Res., 61, 3225 Robertson, 2002, DNA methylation and chromatin—unraveling the tangled web, Oncogene, 21, 5361, 10.1038/sj.onc.1205609 Jaenisch, 2003, Epigenetic regulation of gene expression: how the genome integrates intrinsic and environmental signals, Nat. Genet., 33, 245, 10.1038/ng1089 Jones, 2002, The fundamental role of epigenetic events in cancer, Nat. Rev., Genet., 3, 415, 10.1038/nrg816 Herman, 2003, Gene silencing in cancer in association with promoter hypermethylation, N. Engl. J. Med., 349, 2042, 10.1056/NEJMra023075 De Marzo, 2003, Human prostate cancer precursors and pathobiology, Urology, 62, 55, 10.1016/j.urology.2003.09.053 Rennie, 1998, Epigenetic mechanisms for progression of prostate cancer, Cancer Metastasis Rev., 17, 401, 10.1023/A:1006121219097 Nakayama, 2004, GSTP1 CpG island hypermethylation as a molecular biomarker for prostate cancer, J. Cell. Biochem., 91, 540, 10.1002/jcb.10740 Li, 2003, PGDB: a curated and integrated database of genes related to the prostate, Nucleic Acids Res., 31, 291, 10.1093/nar/gkg008 Chung, 1995, DNA mismatch repair and cancer, Gastroenterology, 109, 1685, 10.1016/0016-5085(95)90660-6 Schofield, 2003, DNA mismatch repair: molecular mechanisms and biological function, Annu. Rev. Microbiol., 57, 579, 10.1146/annurev.micro.57.030502.090847 Harfe, 2000, DNA mismatch repair and genetic instability, Annu. Rev. Genet., 34, 359, 10.1146/annurev.genet.34.1.359 Berhane, 1994, Detoxication of base propenals and other alpha, beta-unsaturated aldehyde products of radical reactions and lipid peroxidation by human glutathione transferases, Proc. Natl. Acad. Sci. U. S. A., 91, 1480, 10.1073/pnas.91.4.1480 Nelson, 2001, Protection against 2-hydroxyamino-1-methyl-6-phenylimidazo[4,5-b]pyridine cytotoxicity and DNA adduct formation in human prostate by glutathione S-transferase P1, Cancer Res., 61, 103 Lee, 1994, Cytidine methylation of regulatory sequences near the pi-class glutathione S-transferase gene accompanies human prostatic carcinogenesis, Proc. Natl. Acad. Sci. U. S. A., 91, 11733, 10.1073/pnas.91.24.11733 Brooks, 1998, CG island methylation changes near the GSTP1 gene in prostatic intraepithelial neoplasia, Cancer Epidemiol. Biomark. Prev., 7, 531 Nakayama, 2003, Hypermethylation of the human glutathione S-transferase-pi gene (GSTP1) CpG island is present in a subset of proliferative inflammatory atrophy lesions but not in normal or hyperplastic epithelium of the prostate: a detailed study using laser-capture microdissection, Am. J. Pathol., 163, 923, 10.1016/S0002-9440(10)63452-9 Esteller, 2004, Generating mutations but providing chemosensitivity: the role of O6-methylguanine DNA methyltransferase in human cancer, Oncogene, 23, 1, 10.1038/sj.onc.1207316 Esteller, 2001, Promoter hypermethylation of the DNA repair gene O(6)-methylguanine-DNA methyltransferase is associated with the presence of G:C to A:T transition mutations in p53 in human colorectal tumorigenesis, Cancer Res., 61, 4689 Maruyama, 2002, Aberrant promoter methylation profile of prostate cancers and its relationship to clinicopathological features, Clin. Cancer Res., 8, 514 Yamanaka, 2003, Altered methylation of multiple genes in carcinogenesis of the prostate, Int. J. Cancer, 106, 382, 10.1002/ijc.11227 Yegnasubramanian, 2004, Hypermethylation of CpG islands in primary and metastatic human prostate cancer, Cancer Res., 64, 1975, 10.1158/0008-5472.CAN-03-3972 Kang, 2004, Aberrant CpG island hypermethylation of multiple genes in prostate cancer and prostatic intraepithelial neoplasia, J. Pathol., 202, 233, 10.1002/path.1503 Konishi, 2002, DNA hypermethylation status of multiple genes in prostate adenocarcinomas, Jpn. J. Cancer Res., 93, 767, 10.1111/j.1349-7006.2002.tb01318.x Greger, 1994, Frequency and parental origin of hypermethylated RB1 alleles in retinoblastoma, Hum. Genet., 94, 491, 10.1007/BF00211013 Veigl, 1998, Biallelic inactivation of hMLH1 by epigenetic gene silencing, a novel mechanism causing human MSI cancers, Proc. Natl. Acad. Sci. U. S. A., 95, 8698, 10.1073/pnas.95.15.8698 Herman, 1994, Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma, Proc. Natl. Acad. Sci. U. S. A., 91, 9700, 10.1073/pnas.91.21.9700 Sekita, 2001, Epigenetic regulation of the KAI1 metastasis suppressor gene in human prostate cancer cell lines, Jpn. J. Cancer Res., 92, 947, 10.1111/j.1349-7006.2001.tb01185.x Schmitt, 2002, Hypermethylation of the inhibin alpha-subunit gene in prostate carcinoma, Mol. Endocrinol., 16, 213, 10.1210/me.16.2.213 Cui, 2001, Hypermethylation of the caveolin-1 gene promoter in prostate cancer, Prostate, 46, 249, 10.1002/1097-0045(20010215)46:3<249::AID-PROS1030>3.0.CO;2-# Chen, 2003, Epigenetic regulation of a novel tumor suppressor gene (hDAB2IP) in prostate cancer cell lines, J. Biol. Chem., 278, 3121, 10.1074/jbc.M208230200 Grossmann, 2001, Androgen receptor signaling in androgen-refractory prostate cancer, J. Natl. Cancer Inst., 93, 1687, 10.1093/jnci/93.22.1687 Jarrard, 1998, Methylation of the androgen receptor promoter CpG island is associated with loss of androgen receptor expression in prostate cancer cells, Cancer Res., 58, 5310 Kinoshita, 2000, Methylation of the androgen receptor minimal promoter silences transcription in human prostate cancer, Cancer Res., 60, 3623 Nakayama, 2000, Epigenetic regulation of androgen receptor gene expression in human prostate cancers, Lab. Invest., 80, 1789, 10.1038/labinvest.3780190 Sasaki, 2002, Methylation and inactivation of estrogen, progesterone, and androgen receptors in prostate cancer, J. Natl. Cancer Inst., 94, 384, 10.1093/jnci/94.5.384 Takahashi, 2002, DNA methylation in the androgen receptor gene promoter region in rat prostate cancers, Prostate, 52, 82, 10.1002/pros.10099 Eder, 2000, Inhibition of LncaP prostate cancer cells by means of androgen receptor antisense oligonucleotides, Cancer Gene Ther., 7, 997, 10.1038/sj.cgt.7700202 Mitchell, 1999, Resveratrol inhibits the expression and function of the androgen receptor in LNCaP prostate cancer cells, Cancer Res., 59, 5892 Tong, 2003, Growth inhibiting effects of antisense eukaryotic expression vector of proliferating cell nuclear antigen gene on human bladder cancer cells, Chin. Med. J. (Engl), 116, 1203 Heisler, 1997, Androgen-dependent cell cycle arrest and apoptotic death in PC-3 prostatic cell cultures expressing a full-length human androgen receptor, Mol. Cell. Endocrinol., 126, 59, 10.1016/S0303-7207(96)03970-6 Huggins, 1965, Two principles in endocrine therapy of cancers: hormone deprival and hormone interference, Cancer Res., 25, 1163 Castagnetta, 1995, Human prostate cancer: a direct role for oestrogens, Ciba Found. Symp., 191, 269 Carruba, 1994, Estradiol inhibits growth of hormone-nonresponsive PC3 human prostate cancer cells, Cancer Res., 54, 1190 Jarred, 2002, Prostate phenotypes in estrogen-modulated transgenic mice, Trends Endocrinol. Metab., 13, 163, 10.1016/S1043-2760(02)00575-1 Leav, 2001, Comparative studies of the estrogen receptors beta and alpha and the androgen receptor in normal human prostate glands, dysplasia, and in primary and metastatic carcinoma, Am. J. Pathol., 159, 79, 10.1016/S0002-9440(10)61676-8 Brolin, 1992, Immunohistochemistry and biochemistry in detection of androgen, progesterone, and estrogen receptors in benign and malignant human prostatic tissue, Prostate, 20, 281, 10.1002/pros.2990200404 Hobisch, 1997, Metastatic lesions from prostate cancer do not express oestrogen and progesterone receptors [see comments], J. Pathol., 182, 356, 10.1002/(SICI)1096-9896(199707)182:3<356::AID-PATH863>3.0.CO;2-U Sonnenschein, 1989, Negative controls of cell proliferation: human prostate cancer cells and androgens, Cancer Res., 49, 3474 Konishi, 1993, Immunohistochemical evaluation of estrogen receptor status in benign prostatic hypertrophy and in prostate carcinoma and the relationship to efficacy of endocrine therapy, Oncology, 50, 259, 10.1159/000227191 Li, 2000, Frequent methylation of estrogen receptor in prostate cancer: correlation with tumor progression, Cancer Res., 60, 702 Lau, 2000, Expression of estrogen receptor (ER)-alpha and ER-beta in normal and malignant prostatic epithelial cells: regulation by methylation and involvement in growth regulation, Cancer Res., 60, 3175 Issa, 1994, Methylation of the oestrogen receptor CpG island links ageing and neoplasia in human colon, Nat. Genet., 7, 536, 10.1038/ng0894-536 Lapidus, 1996, Methylation of estrogen and progesterone receptor gene 5' CpG islands correlates with lack of estrogen and progesterone receptor gene expression in breast tumors, Clin. Cancer Res., 2, 805 Issa, 1996, Methylation of the estrogen receptor CpG island in lung tumors is related to the specific type of carcinogen exposure, Cancer Res., 56, 3655 Horvath, 2001, Frequent loss of estrogen receptor-beta expression in prostate cancer, Cancer Res., 61, 5331 Pasquali, 2001, Loss of estrogen receptor beta expression in malignant human prostate cells in primary cultures and in prostate cancer tissues, J. Clin. Endocrinol. Metab., 86, 2051, 10.1210/jc.86.5.2051 Li, 2000, Cloning and characterization of human estrogen receptor beta promoter, Biochem. Biophys. Res. Commun., 275, 682, 10.1006/bbrc.2000.3363 Nojima, 2001, CpG hypermethylation of the promoter region inactivates the estrogen receptor-beta gene in patients with prostate carcinoma, Cancer, 92, 2076, 10.1002/1097-0142(20011015)92:8<2076::AID-CNCR1548>3.0.CO;2-A De Luca, 1991, Retinoids and their receptors in differentiation, embryogenesis, and neoplasia, FASEB J., 5, 2924, 10.1096/fasebj.5.14.1661245 Liu, 1996, Retinoic acid receptor beta mediates the growth-inhibitory effect of retinoic acid by promoting apoptosis in human breast cancer cells, Mol. Cell. Biol., 16, 1138, 10.1128/MCB.16.3.1138 Lotan, 2000, Differential expression of nuclear retinoid receptors in normal and malignant prostates, J. Clin. Oncol., 18, 116, 10.1200/JCO.2000.18.1.116 Kikugawa, 2000, Immunohistochemical study of the receptors for retinoic acid in prostatic adenocarcinoma, Anticancer Res., 20, 3897 van der Leede, 1992, Genomic organization of the human retinoic acid receptor beta 2, Biochem. Biophys. Res. Commun., 188, 695, 10.1016/0006-291X(92)91112-4 Yang, 2001, Biallelic inactivation of retinoic acid receptor beta2 gene by epigenetic change in breast cancer, Am. J. Pathol., 158, 299, 10.1016/S0002-9440(10)63969-7 Ivanova, 2002, Methylation and silencing of the retinoic acid receptor-beta 2 gene in cervical cancer, BMC Cancer, 2, 4, 10.1186/1471-2407-2-4 Maruyama, 2001, Aberrant promoter methylation profile of bladder cancer and its relationship to clinicopathological features, Cancer Res., 61, 8659 Nakayama, 2001, The role of epigenetic modifications in retinoic acid receptor beta2 gene expression in human prostate cancers, Lab. Invest., 81, 1049, 10.1038/labinvest.3780316 Fernandez, 1998, Cell cycle regulators and their abnormalities in breast cancer, Mol. Pathol., 51, 305, 10.1136/mp.51.6.305 Swanton, 2004, Cell-cycle targeted therapies, Lancet Oncol., 5, 27, 10.1016/S1470-2045(03)01321-4 Malumbres, 2001, To cycle or not to cycle: a critical decision in cancer, Nat. Rev., Cancer, 1, 222, 10.1038/35106065 Aaltomaa, 1999, Prognostic value and expression of p21(waf1/cip1) protein in prostate cancer, Prostate, 39, 8, 10.1002/(SICI)1097-0045(19990401)39:1<8::AID-PROS2>3.0.CO;2-N Cote, 1998, Association of p27Kip1 levels with recurrence and survival in patients with stage C prostate carcinoma, J. Natl. Cancer Inst., 90, 916, 10.1093/jnci/90.12.916 Cairns, 1995, Frequency of homozygous deletion at p16/CDKN2 in primary human tumours, Nat. Genet., 11, 210, 10.1038/ng1095-210 Koh, 1995, Tumour-derived p16 alleles encoding proteins defective in cell-cycle inhibition, Nature, 375, 506, 10.1038/375506a0 Okamoto, 1994, p16INK4 mutations and altered expression in human tumors and cell lines, Cold Spring Harbor Symp. Quant. Biol., 59, 49, 10.1101/SQB.1994.059.01.008 Otterson, 1994, Absence of p16INK4 protein is restricted to the subset of lung cancer lines that retains wildtype RB, Oncogene, 9, 3375 Herman, 1995, Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers, Cancer Res., 55, 4525 Jarrard, 1997, Deletional, mutational, and methylation analyses of CDKN2 (p16/MTS1) in primary and metastatic prostate cancer, Genes Chromosomes Cancer, 19, 90, 10.1002/(SICI)1098-2264(199706)19:2<90::AID-GCC4>3.0.CO;2-V Gu, 1998, Analysis of the p16 tumor suppressor gene in early-stage prostate cancer, Mol. Carcinog., 21, 164, 10.1002/(SICI)1098-2744(199803)21:3<164::AID-MC3>3.0.CO;2-M Nguyen, 2000, Analysis of cyclin-dependent kinase inhibitor expression and methylation patterns in human prostate cancers, Prostate, 43, 233, 10.1002/(SICI)1097-0045(20000515)43:3<233::AID-PROS10>3.0.CO;2-S Song, 2004, The tumour suppressor RASSF1A regulates mitosis by inhibiting the APC–Cdc20 complex, Nat. Cell Biol., 6, 129, 10.1038/ncb1091 Vos, 2000, Ras uses the novel tumor suppressor RASSF1 as an effector to mediate apoptosis, J. Biol. Chem., 275, 35669, 10.1074/jbc.C000463200 Dammann, 2000, Epigenetic inactivation of a RAS association domain family protein from the lung tumour suppressor locus 3p21.3, Nat. Genet., 25, 315, 10.1038/77083 Liu, 2002, Frequent hypermethylation of the RASSF1A gene in prostate cancer, Oncogene, 21, 6835, 10.1038/sj.onc.1205814 Kuzmin, 2002, The RASSF1A tumor suppressor gene is inactivated in prostate tumors and suppresses growth of prostate carcinoma cells, Cancer Res., 62, 3498 Morrissey, 2001, Epigenetic inactivation of the RASSF1A 3p21.3 tumor suppressor gene in both clear cell and papillary renal cell carcinoma, Cancer Res., 61, 7277 Astuti, 2001, RASSF1A promoter region CpG island hypermethylation in phaeochromocytomas and neuroblastoma tumours, Oncogene, 20, 7573, 10.1038/sj.onc.1204968 Burbee, 2001, Epigenetic inactivation of RASSF1A in lung and breast cancers and malignant phenotype suppression, J. Natl. Cancer Inst., 93, 691, 10.1093/jnci/93.9.691 Murray, 2004, Frequent epigenetic inactivation of the RASSF1A tumor suppressor gene in Hodgkin's lymphoma, Oncogene, 23, 1326, 10.1038/sj.onc.1207313 Wong, 2004, Ubiquitous aberrant RASSF1A promoter methylation in childhood neoplasia(1), Clin. Cancer Res., 10, 994, 10.1158/1078-0432.CCR-0378-3 Yoon, 2001, Hypermethylation of the CpG island of the RASSF1A gene in ovarian and renal cell carcinomas, Int. J. Cancer, 94, 212, 10.1002/ijc.1466 Lee, 2001, Frequent epigenetic inactivation of RASSF1A in human bladder carcinoma, Cancer Res., 61, 6688 Woodson, 2004, A survey of gene-specific methylation in human prostate cancer among black and white men, Cancer Lett., 205, 181, 10.1016/j.canlet.2003.11.027 Stetler-Stevenson, 1993, Tumor cell interactions with the extracellular matrix during invasion and metastasis, Annu. Rev. Cell. Biol., 9, 541, 10.1146/annurev.cb.09.110193.002545 Takeichi, 1991, Cadherin cell adhesion receptors as a morphogenetic regulator, Science, 251, 1451, 10.1126/science.2006419 Bremnes, 2002, The E-cadherin cell–cell adhesion complex and lung cancer invasion, metastasis, and prognosis, Lung Cancer, 36, 115, 10.1016/S0169-5002(01)00471-8 Berx, 2001, The E-cadherin/catenin complex: an important gatekeeper in breast cancer tumorigenesis and malignant progression, Breast Cancer Res., 3, 289, 10.1186/bcr309 Wheelock, 2003, Cadherin-mediated cellular signaling, Curr. Opin. Cell. Biol., 15, 509, 10.1016/S0955-0674(03)00101-7 Krishnadath, 1997, Reduced expression of the cadherin–catenin complex in oesophageal adenocarcinoma correlates with poor prognosis, J. Pathol., 182, 331, 10.1002/(SICI)1096-9896(199707)182:3<331::AID-PATH860>3.0.CO;2-D Richmond, 1997, Aberrant E-cadherin and alpha-catenin expression in prostate cancer: correlation with patient survival, Cancer Res., 57, 3189 Hirohashi, 1998, Inactivation of the E-cadherin-mediated cell adhesion system in human cancers, Am. J. Pathol., 153, 333, 10.1016/S0002-9440(10)65575-7 Graff, 1995, E-cadherin expression is silenced by DNA hypermethylation in human breast and prostate carcinomas, Cancer Res., 55, 5195 Li, 2001, Methylation of the E-cadherin gene promoter correlates with progression of prostate cancer, J. Urol., 166, 705, 10.1016/S0022-5347(05)66047-8 Kanai, 1997, The E-cadherin gene is silenced by CpG methylation in human hepatocellular carcinomas, Int. J. Cancer., 71, 355, 10.1002/(SICI)1097-0215(19970502)71:3<355::AID-IJC8>3.0.CO;2-X Saito, 1998, Reduced expression of E-cadherin in oral squamous cell carcinoma: relationship with DNA methylation of 5' CpG island, Int. J. Oncol., 12, 293 Yoshiura, 1995, Silencing of the E-cadherin invasion-suppressor gene by CpG methylation in human carcinomas, Proc. Natl. Acad. Sci. U. S. A., 92, 7416, 10.1073/pnas.92.16.7416 Corn, 2000, E-cadherin expression is silenced by 5' CpG island methylation in acute leukemia, Clin. Cancer Res., 6, 4243 Kallakury, 2001, Decreased expression of catenins (alpha and beta), p120 CTN, and E-cadherin cell adhesion proteins and E-cadherin gene promoter methylation in prostatic adenocarcinomas, Cancer, 92, 2786, 10.1002/1097-0142(20011201)92:11<2786::AID-CNCR10128>3.0.CO;2-I Woodson, 2003, Hypermethylation of GSTP1, CD44, and E-cadherin genes in prostate cancer among US blacks and whites, Prostate, 55, 199, 10.1002/pros.10236 Gao, 1997, CD44 is a metastasis suppressor gene for prostatic cancer located on human chromosome 11p13, Cancer Res., 57, 846 Verkaik, 2000, Silencing of CD44 expression in prostate cancer by hypermethylation of the D44 promoter region, Lab. Invest., 80, 1291, 10.1038/labinvest.3780137 Vis, 2001, Feasibility of assessment of promoter methylation of the CD44 gene in serum of prostate cancer patients, Mol. Urol., 5, 199, 10.1089/10915360152745894 Kito, 2001, Hypermethylation of the CD44 gene is associated with progression and metastasis of human prostate cancer, Prostate, 49, 110, 10.1002/pros.1124 Lou, 1999, Methylation of the CD44 metastasis suppressor gene in human prostate cancer, Cancer Res., 59, 2329 Verkaik, 1999, Down-regulation of CD44 expression in human prostatic carcinoma cell lines is correlated with DNA hypermethylation, Int. J. Cancer, 80, 439, 10.1002/(SICI)1097-0215(19990129)80:3<439::AID-IJC17>3.0.CO;2-V Noordzij, 1997, The prognostic value of CD44 isoforms in prostate cancer patients treated by radical prostatectomy, Clin. Cancer Res., 3, 805 Fearnhead, 2001, The ABC of APC, Hum. Mol. Genet., 10, 721, 10.1093/hmg/10.7.721 Nathke, 1999, The adenomatous polyposis coli protein, Mol. Pathol., 52, 169, 10.1136/mp.52.4.169 Bostwick, 1987, Prostatic intra-epithelial neoplasia and early invasion in prostate cancer, Cancer, 59, 788, 10.1002/1097-0142(19870215)59:4<788::AID-CNCR2820590421>3.0.CO;2-I Vis, 2001, Prostatic intraepithelial neoplasia and putative precursor lesions of prostate cancer: a clinical perspective, BJU Int., 88, 147, 10.1046/j.1464-410x.2001.02295.x De Marzo, 1999, Proliferative inflammatory atrophy of the prostate: implications for prostatic carcinogenesis, Am. J. Pathol., 155, 1985, 10.1016/S0002-9440(10)65517-4 Esteller, 2000, Epigenetic lesions causing genetic lesions in human cancer: promoter hypermethylation of DNA repair genes, Eur. J. Cancer, 36, 2294, 10.1016/S0959-8049(00)00303-8 Ferraz, 2004, Impact of GSTT1, GSTM1, GSTP1 and NAT2 genotypes on KRAS2 and TP53 gene mutations in colorectal cancer, Int. J. Cancer, 110, 183, 10.1002/ijc.20124 Gudmundsdottir, 2001, GSTM1, GSTT1, and GSTP1 genotypes in relation to breast cancer risk and frequency of mutations in the p53 gene, Cancer Epidemiol. Biomark. Prev., 10, 1169 Kote-Jarai, 2001, Relationship between glutathione S-transferase M1, P1 and T1 polymorphisms and early onset prostate cancer, Pharmacogenetics, 11, 325, 10.1097/00008571-200106000-00007 Nelson, 2002, The diet, prostate inflammation, and the development of prostate cancer, Cancer Metastasis Rev., 21, 3, 10.1023/A:1020110718701 Sakr, 1993, The frequency of carcinoma and intraepithelial neoplasia of the prostate in young male patients, J. Urol., 150, 379, 10.1016/S0022-5347(17)35487-3 Izbicka, 1999, 5,6 Dihydro-5'-azacytidine (DHAC) restores androgen responsiveness in androgen-insensitive prostate cancer cells, Anticancer Res., 19, 1285 Wu, 2004, PMP24, a gene identified by MSRF, undergoes DNA hypermethylation-associated gene silencing during cancer progression in an LNCaP model, Oncogene, 23, 250, 10.1038/sj.onc.1207076 Santourlidis, 1999, High frequency of alterations in DNA methylation in adenocarcinoma of the prostate, Prostate, 39, 166, 10.1002/(SICI)1097-0045(19990515)39:3<166::AID-PROS4>3.0.CO;2-J Lee, 1997, CG island methylation changes near the GSTP1 gene in prostatic carcinoma cells detected using the polymerase chain reaction: a new prostate cancer biomarker, Cancer Epidemiol. Biomark. Prev., 6, 443 Battagli, 2003, Promoter hypermethylation of tumor suppressor genes in urine from kidney cancer patients, Cancer Res., 63, 8659 Kane, 1997, Methylation of the hMLH1 promoter correlates with lack of expression of hMLH1 in sporadic colon tumors and mismatch repair-defective human tumor cell lines, Cancer Res., 57, 808 Ricciardiello, 2003, Frequent loss of hMLH1 by promoter hypermethylation leads to microsatellite instability in adenomatous polyps of patients with a single first-degree member affected by colon cancer, Cancer Res., 63, 787 Kawakami, 2000, Hypermethylated APC DNA in plasma and prognosis of patients with esophageal adenocarcinoma, J. Natl. Cancer Inst., 92, 1805, 10.1093/jnci/92.22.1805 Jeronimo, 2003, Endothelin B receptor gene hypermethylation in prostate adenocarcinoma, J. Clin. Pathol., 56, 52, 10.1136/jcp.56.1.52 Ahuja, 1998, Aging and DNA methylation in colorectal mucosa and cancer, Cancer Res., 58, 5489 Post, 1999, Methylation of the estrogen receptor gene is associated with aging and atherosclerosis in the cardiovascular system, Cardiovasc. Res., 43, 985, 10.1016/S0008-6363(99)00153-4 Ahuja, 2000, Aging, methylation and cancer, Histol. Histopathol., 15, 835 Toyota, 1999, CpG island methylator phenotypes in aging and cancer, Semin. Cancer Biol., 9, 349, 10.1006/scbi.1999.0135 Toyota, 1999, CpG island methylator phenotype in colorectal cancer, Proc. Natl. Acad. Sci. U. S. A., 96, 8681, 10.1073/pnas.96.15.8681 Hankey, 1999, Cancer surveillance series: interpreting trends in prostate cancer–part I. Evidence of the effects of screening in recent prostate cancer incidence, mortality, and survival rates, J. Natl. Cancer Inst., 91, 1017, 10.1093/jnci/91.12.1017 Hoffman, 2001, Racial and ethnic differences in advanced-stage prostate cancer: the Prostate Cancer Outcomes Study, J. Natl. Cancer Inst., 93, 388, 10.1093/jnci/93.5.388 Powell, 1999, Should African-American men be tested for prostate carcinoma at an earlier age than white men?, Cancer, 85, 472, 10.1002/(SICI)1097-0142(19990115)85:2<472::AID-CNCR27>3.0.CO;2-0 Powell, 2001, African-American heredity prostate cancer study: a model for genetic research, J. Natl. Med. Assoc., 93, 120 Cotter, 2002, Role of family history and ethnicity on the mode and age of prostate cancer presentation, Prostate, 50, 216, 10.1002/pros.10051 Zeegers, 2003, Empiric risk of prostate carcinoma for relatives of patients with prostate carcinoma: a meta-analysis, Cancer, 97, 1894, 10.1002/cncr.11262 Schaid, 2004, The complex genetic epidemiology of prostate cancer, Hum. Mol. Genet., 15, R103, 10.1093/hmg/ddh072 Frazier, 2003, Association of the CpG island methylator phenotype with family history of cancer in patients with colorectal cancer, Cancer Res., 63, 4805 Brock, 2003, Prognostic importance of promoter hypermethylation of multiple genes in sophageal adenocarcinoma, Clin. Cancer Res., 9, 2912 Rhodes, 2003, Multiplex biomarker approach for determining risk of prostate-specific antigen-defined recurrence of prostate cancer, J. Natl. Cancer Inst., 95, 661, 10.1093/jnci/95.9.661 Goessl, 2001, DNA-based detection of prostate cancer in urine after prostatic massage, Urology, 58, 335, 10.1016/S0090-4295(01)01268-7 Cairns, 2001, Molecular detection of prostate cancer in urine by GSTP1 hypermethylation, Clin. Cancer Res., 7, 2727 Gonzalgo, 2003, Prostate cancer detection by GSTP1 methylation analysis of postbiopsy urine specimens, Clin. Cancer Res., 9, 2673 Goessl, 2000, Fluorescent methylation-specific polymerase chain reaction for DNA-based detection of prostate cancer in bodily fluids, Cancer Res., 60, 5941 Suh, 2000, Comparison of telomerase activity and GSTP1 promoter methylation in ejaculate as potential screening tests for prostate cancer, Mol. Cell. Probes, 14, 211, 10.1006/mcpr.2000.0307 Jeronimo, 2002, I105V polymorphism and promoter methylation of the GSTP1 gene in prostate adenocarcinoma, Cancer Epidemiol. Biomark. Prev., 11, 445 Costello, 2000, Aberrant CpG-island methylation has non-random and tumour-type-specific patterns, Nat. Genet., 24, 132, 10.1038/72785 Huang, 1999, Methylation profiling of CpG islands in human breast cancer cells, Hum. Mol Genet., 8, 459, 10.1093/hmg/8.3.459 Padar, 2003, Inactivation of cyclin D2 gene in prostate cancers by aberrant promoter methylation, Clin. Cancer Res., 9, 4730 Singal, 2001, Cytosine methylation represses glutathione S-transferase P1 (GSTP1) gene expression in human prostate cancer cells, Cancer Res., 61, 4820 Jeronimo, 2001, Quantitation of GSTP1 methylation in non-neoplastic prostatic tissue and organ-confined prostate adenocarcinoma, J. Natl. Cancer Inst., 93, 1747, 10.1093/jnci/93.22.1747 Goessl, 2002, Methylation-specific PCR for detection of neoplastic DNA in biopsy washings, J. Pathol., 196, 331, 10.1002/path.1063 Harden, 2003, Quantitative GSTP1 methylation clearly distinguishes benign prostatic tissue and limited prostate adenocarcinoma, J. Urol., 169, 1138, 10.1097/01.ju.0000049627.90307.4d Kollermann, 2003, Methylation-specific PCR for DNA-based detection of occult tumor cells in lymph nodes of prostate cancer patients, Eur. Urol., 44, 533, 10.1016/S0302-2838(03)00361-0 Sathyanarayana, 2003, Aberrant promoter methylation of laminin-5-encoding genes in prostate cancers and its relationship to clinicopathological features, Clin. Cancer Res., 9, 6395 Zhang, 2003, Methylation of the retinoid response gene TIG1 in prostate cancer correlates with methylation of the retinoic acid receptor beta gene, Oncogene, 23, 2241, 10.1038/sj.onc.1207328